272 results on '"Carta, Manolo"'
Search Results
2. Expanding the therapeutic potential of neuro(active)steroids: a promising strategy for hyperdopaminergic behavioral phenotypes
3. SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
4. Perturbation of serine enantiomers homeostasis in the striatum of MPTP-lesioned monkeys and mice reflects the extent of dopaminergic midbrain degeneration
5. Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease
6. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson’s disease
7. Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients
8. Corrigendum to “Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease” [Experimental neurology 2023 May;363:114370]
9. Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding
10. VGF peptides as novel biomarkers in Parkinson’s disease
11. Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update
12. Assessment of Nonmotor Symptoms in Rodent Models of Parkinson’s Disease
13. The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective
14. The Serotonergic System in Levodopa-Induced Dyskinesia
15. The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients
16. Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
17. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease
18. Chronic tryptophan deprivation attenuates gating deficits induced by 5-HT1A, but not 5-HT2 receptor activation
19. 5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation
20. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinsonʼs disease
21. Amphetamine Usage, Misuse, and Addiction Processes
22. List of Contributors
23. Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia
24. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinsonʼs disease
25. On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats
26. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson’s disease
27. Dyskinesia in Parkinson’s disease: a clinical complication and an open scientific question
28. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinsonʼs disease
29. Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson’s disease?
30. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT 1A and 5-HT 1B receptor agonists in the rat Parkinson model
31. Involvement of the serotonin system in l-dopa-induced dyskinesias
32. Effects of tryptophan deficiency on prepulse inhibition of the acoustic startle in rats
33. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
34. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression
35. BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia
36. Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease
37. Essential fatty acids deficient diet modulates N-Acylethanolamide profile in rat's tissues
38. VGF peptides as novel biomarkers in Parkinson’s disease
39. Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson’s disease
40. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinsonʼs disease
41. Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats
42. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model
43. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration
44. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
45. The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons
46. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
47. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats
48. Altered dopaminergic innervation and amphetamine response in adult Otx2 conditional mutant mice
49. Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia
50. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.